Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Rosa I. Gallagher"'
Autor:
Nur P. Damayanti, M. Reza Saadatzadeh, Erika Dobrota, Josue D. Ordaz, Barbara J. Bailey, Pankita H. Pandya, Khadijeh Bijangi-Vishehsaraei, Harlan E. Shannon, Anthony Alfonso, Kathy Coy, Melissa Trowbridge, Anthony L. Sinn, Zhong-Yin Zhang, Rosa I. Gallagher, Julia Wulfkuhle, Emanuel Petricoin, Angela M. Richardson, Mark S. Marshall, Alex Lion, Michael J. Ferguson, Karl E. Balsara, Karen E. Pollok
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-18 (2023)
Abstract Pleomorphic xanthoastrocytoma (PXA) is a rare subset of primary pediatric glioma with 70% 5-year disease free survival. However, up to 20% of cases present with local recurrence and malignant transformation into more aggressive type anaplast
Externí odkaz:
https://doaj.org/article/e5789262b3ec42119349962b8c13096b
Autor:
Anthony D. Elias, Nicole S. Spoelstra, Alyse W. Staley, Sharon Sams, Lyndsey S. Crump, Gregory A. Vidal, Virginia F. Borges, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Angelo D’Alessandro, Kathryn L. Zolman, Adrie van Bokhoven, Yonghua Zhuang, Rosa I. Gallagher, Julia D. Wulfkuhle, Emanuel F. Petricoin III, Dexiang Gao, Jennifer K. Richer
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract This clinical trial combined fulvestrant with the anti-androgen enzalutamide in women with metastatic ER+/HER2− breast cancer (BC). Eligible patients were women with ECOG 0–2, ER+/HER2− measurable or evaluable metastatic BC. Prior fulv
Externí odkaz:
https://doaj.org/article/ad0c82b5d82a4e81a6170a0a923d1435
Autor:
Mariaelena Pierobon, Nicholas J. Robert, Donald W. Northfelt, Mohammad Jahanzeb, Shukmei Wong, Kimberly A. Hodge, Elisa Baldelli, Jessica Aldrich, David W. Craig, Lance A. Liotta, Sanja Avramovic, Janusz Wojtusiak, Farrokh Alemi, Julia D. Wulfkuhle, Angela Bellos, Rosa I. Gallagher, David Arguello, Amber Conrad, Ariane Kemkes, David M. Loesch, Linda Vocila, Bryant Dunetz, John D. Carpten, Emanuel F. Petricoin, Stephen P. Anthony
Publikováno v:
Molecular Oncology, Vol 16, Iss 1, Pp 104-115 (2022)
This prospective phase II clinical trial (Side Out 2) explored the clinical benefits of treatment selection informed by multi‐omic molecular profiling (MoMP) in refractory metastatic breast cancers (MBCs). Core needle biopsies were collected from 3
Externí odkaz:
https://doaj.org/article/a34e1099108d4ecd8b5fb3cad6ddfdec
Autor:
Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van ‘t Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa I. Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pert
Externí odkaz:
https://doaj.org/article/e6340916dac6476fac8b24ed5afd32c1
Autor:
Pankita H. Pandya, Asha Jacob Jannu, Khadijeh Bijangi-Vishehsaraei, Erika Dobrota, Barbara J. Bailey, Farinaz Barghi, Harlan E. Shannon, Niknam Riyahi, Nur P. Damayanti, Courtney Young, Rada Malko, Ryli Justice, Eric Albright, George E. Sandusky, L. Daniel Wurtz, Christopher D. Collier, Mark S. Marshall, Rosa I. Gallagher, Julia D. Wulfkuhle, Emanuel F. Petricoin, Kathy Coy, Melissa Trowbridge, Anthony L. Sinn, Jamie L. Renbarger, Michael J. Ferguson, Kun Huang, Jie Zhang, M. Reza Saadatzadeh, Karen E. Pollok
Publikováno v:
Cancers, Vol 15, Iss 1, p 259 (2022)
Establishment of clinically annotated, molecularly characterized, patient-derived xenografts (PDXs) from treatment-naïve and pretreated patients provides a platform to test precision genomics-guided therapies. An integrated multi-OMICS pipeline was
Externí odkaz:
https://doaj.org/article/e4a18dcf94ec48d8859f566e1d55abda
Autor:
Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
Publikováno v:
Blood Advances, Vol 1, Iss 14, Pp 933-946 (2017)
Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable response
Externí odkaz:
https://doaj.org/article/8971b2c6746d4ca78045d1f18e8e94de
Autor:
Julia Wulfkuhle, Page Blas, Heather Williams, Claudius Mueller, Rosa I. Gallagher, Mariaelena Pierobon, Joyce O’Shaughnessy, Emanuel F. Petricoin
Publikováno v:
Cancer Research. 83:PD5-08
Title: Drug target activation mapping of matched triple negative primary and axillary LN metastases identifies and links the ER-AR-GR steroid hormone receptor axis with downstream AKT activation Background: Triple negative breast cancer (TNBC) is com
Publikováno v:
Cancer Research. 83:P4-08
Breast cancer is the major leading cause of cancer-related fatalities nationally and globally. There will be 287,850 new breast cancer cases and 43,250 breast cancer related deaths in the United States in 2022. The relapsed, treatment-resistant, undr
Autor:
Steven J. Isakoff, Mafalda Oliveira, Emanuel F. Petricoin, Matthew J. Wongchenko, Patricia Villagrasa, Eva M. Ciruelos, Debra A. Pratt, Begoña Bermejo, Miguel J. Gil-Gil, José Luis Passos-Coelho, Jay Andersen, Isabel Calvo, Paolo G. Nuciforo, Cristina Saura, Rosa I. Gallagher, Malgorzata Nowicka, Julia Wulfkuhle, Zhen Shi
Purpose:Despite extensive genomic and transcriptomic profiling, it remains unknown how signaling pathways are differentially activated and how tumors are differentially sensitized to certain perturbations. Here, we aim to characterize AKT signaling a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e2eca09880115d1cf4d33de9bed5dff
https://doi.org/10.1158/1078-0432.c.6531054.v1
https://doi.org/10.1158/1078-0432.c.6531054.v1
Autor:
Emanuel F. Petricoin, John D. Carpten, Joyce A. O'Shaughnessy, Lance A. Liotta, Brian Leyland-Jones, Massimo Cristofanilli, David W. Craig, Ting Dong, Nicholas Hoke, Bryant Dunetz, Rosa I. Gallagher, Guido Gambara, Julia Wulfkuhle, Linda Vocila, Mohammad Jahanzeb, Donald W. Northfelt, Nicholas J. Robert, Stephen P. Anthony, Sara Byron, Jessica Aldrich, K. Alex Hodge, Shukmei Wong, Corinne Ramos, Mariaelena Pierobon
AKT S473 distribution based on ER, HER2 expression measured by IHC in for primary and metastatic lesions included in the validation set.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f391afae235a8ac682b897d3a84a489
https://doi.org/10.1158/1078-0432.22462946.v1
https://doi.org/10.1158/1078-0432.22462946.v1